EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DEVELOPMENTS

1 Drugs in Development

1 Drugs in Development

DIGITAL CONTENT

1 NEWS #PharmaBuzz

media
1 NEWS #PharmaBuzz

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

1DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: Tak-659, 1312691-33-0, Tak-659 free base, Mivavotinib [usan], Tak-659f, Tak659

Molecular Formula

C₁₇H₂₁FN₆O

Molecular Weight

344.4 g/mol

InChI Key

MJHOMTRKVMKCNE-NWDGAFQWSA-N

FDA UNII

8QR88H79VX

Mivavotinib is an inhibitor of spleen tyrosine kinase (syk), with potential anti-inflammatory, immunomodulating, and antineoplastic activities. Upon administration, mivavotinib may inhibit the activity of syk, which abrogates downstream B-cell receptor (BCR) signaling and leads to an inhibition of B-cell activation, chemotaxis, adhesion and proliferation. Syk, a BCR-associated non-receptor tyrosine kinase that mediates diverse cellular responses, including proliferation, differentiation, and phagocytosis, is expressed in hematopoietic tissues and is often overexpressed in hematopoietic malignancies.

1 2D Structure

Mivavotinib

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

6-[[(1R,2S)-2-aminocyclohexyl]amino]-7-fluoro-4-(1-methylpyrazol-4-yl)-1,2-dihydropyrrolo[3,4-c]pyridin-3-one

2.1.2 InChI

InChI=1S/C17H21FN6O/c1-24-8-9(6-21-24)15-13-10(7-20-17(13)25)14(18)16(23-15)22-12-5-3-2-4-11(12)19/h6,8,11-12H,2-5,7,19H2,1H3,(H,20,25)(H,22,23)/t11-,12+/m0/s1

2.1.3 InChI Key

MJHOMTRKVMKCNE-NWDGAFQWSA-N

2.1.4 Canonical SMILES

CN1C=C(C=N1)C2=NC(=C(C3=C2C(=O)NC3)F)NC4CCCCC4N

2.1.5 Isomeric SMILES

CN1C=C(C=N1)C2=NC(=C(C3=C2C(=O)NC3)F)N[C@@H]4CCCC[C@@H]4N

2.2 Other Identifiers

2.2.1 UNII

8QR88H79VX

2.3 Synonyms

2.3.1 MeSH Synonyms

1. Tak-659

2.3.2 Depositor-Supplied Synonyms

1. Tak-659

2. 1312691-33-0

3. Tak-659 Free Base

4. Mivavotinib [usan]

5. Tak-659f

6. Tak659

7. 8qr88h79vx

8. Chembl3979920

9. 6-[[(1r,2s)-2-aminocyclohexyl]amino]-7-fluoro-4-(1-methylpyrazol-4-yl)-1,2-dihydropyrrolo[3,4-c]pyridin-3-one

10. 3h-pyrrolo(3,4-c)pyridin-3-one, 6-(((1r,2s)-2-aminocyclohexyl)amino)-7-fluoro-1,2-dihydro-4-(1-methyl-1h-pyrazol-4-yl)-

11. 3h-pyrrolo[3,4-c]pyridin-3-one, 6-[[(1r,2s)-2-aminocyclohexyl]amino]-7-fluoro-1,2-dihydro-4-(1-methyl-1h-pyrazol-4-yl)-

12. 6-(((1r,2s)-2-aminocyclohexyl)amino)-7-fluoro-4-(1-methyl-1h-pyrazol-4-yl)-1,2-dihydro-3h-pyrrolo[3,4-c]pyridin-3-one

13. 6-((1r,2s)-2-aminocyclohexylamino)-7-fluoro-4-(1-methyl-1h-pyrazol-4-yl)-1h-pyrrolo(3,4-c)pyridin-3(2h)-one

14. 6-((1r,2s)-2-aminocyclohexylamino)-7-fluoro-4-(1-methyl-1h-pyrazol-4-yl)-1h-pyrrolo[3,4-c]pyridin-3(2h)-one

15. 6-{[(1r,2s)-2-aminocyclohexyl]amino}-7-fluoro-4-(1-methyl-1h-pyrazol-4-yl)-1,2-dihydro-3h-pyrrolo[3,4-c]pyridin-3-one

16. Mivavotinib [inn]

17. Mivavotinib (usan/inn)

18. Tak659 2hcl

19. Unii-8qr88h79vx

20. Mivavotinib [who-dd]

21. Tak-659 2hcl

22. Gtpl9600

23. Schembl1987799

24. Tak-659 Free Base(mivavotinib)

25. Bcp28883

26. Ex-a1401

27. Bdbm50204290

28. Cb-659

29. Nsc791967

30. Nsc791968

31. Who 10836

32. Nsc-791967

33. Nsc-791968

34. Compound 3b [pmid: 27839918]

35. Ac-35463

36. Hy-100867

37. Cs-0020533

38. D11789

39. 1312691-41-0

40. Cis-6-(2-aminocyclohexylamino)-7-fluoro-4-(1-methyl-1h-pyrazol-4-yl)-1h-pyrrolo[3,4-c]pyridin-3(2h)-one

2.4 Create Date

2011-07-25

3 Chemical and Physical Properties

Molecular Formula	C₁₇H₂₁FN₆O
Molecular Weight	344.4 g/mol
XLogP3	0.5
Hydrogen Bond Donor Count	3
Hydrogen Bond Acceptor Count	6
Rotatable Bond Count	3
Exact Mass	344.17608748 g/mol
Monoisotopic Mass	344.17608748 g/mol
Topological Polar Surface Area	97.9 Å²
Heavy Atom Count	25
Formal Charge	0
Complexity	508
Isotope Atom Count	0
Defined Atom Stereocenter Count	2
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1